HER2and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial

Determination of HER2 amplification by in situ hybridization: when should chromosome 17 also be determined?.

(2010) JM Bartlett et al.   CANCER RESEARCH

Chromosome 17 polysomy: a unifying hypothesis underlying benefit from adjuvant anthracyclines?.

(2010) JM Bartlett et al.   CANCER RESEARCH

Do the ASCO/CAP 2007 HER2 Testing Guidelines Improve Prediction of Benefit to Adjuvant Trastuzumab?: Data from North Central Cancer Treatment Group N9831 Adjuvant Trial.

(2010) E. Perez et al.   CANCER RESEARCH

HER-2, Notch, and Breast Cancer Stem Cells: Targeting an Axis of Evil

(2009) H. Korkaya et al.   CLINICAL CANCER RESEARCH

Tumor-Initiating Cells of HER2-Positive Carcinoma Cell Lines Express the Highest Oncoprotein Levels and Are Sensitive to Trastuzumab

(2009) A. Magnifico et al.   CLINICAL CANCER RESEARCH

Disease-Free Survival According to Degree ofHER2Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial

(2009) Mitch Dowsett et al.   JOURNAL OF CLINICAL ONCOLOGY

Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response

(2009) Monica M Reinholz et al.   LANCET ONCOLOGY

Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab

(2008) F. Peintinger et al.   ANNALS OF ONCOLOGY

Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial

(2008) M. Untch et al.   ANNALS OF ONCOLOGY

The genomic profile ofHER2-amplified breast cancers: the influence of ER status

(2008) C Marchiò et al.   JOURNAL OF PATHOLOGY

HER2Status and Benefit from Adjuvant Trastuzumab in Breast Cancer

(2008) Soonmyung Paik et al.   NEW ENGLAND JOURNAL OF MEDICINE